All Posts

Top Liquid Biopsy Companies
Top Five Liquid Biopsy Companies Impacting Cancer Diagnostics Market from 2020 to 2028

Cancer diagnostics is an umbrella term that encompasses all diagnostics modalities such as imaging, molecular diagnostics, and biopsy employed in drawing conclusions regarding cancer diagnosis and devising prognostic strategies.  Liquid Biopsy is comparatively a new technique in the cancer diagnosis and the...

Find More

Radicava for ALS
Amyotrophic Lateral Sclerosis Treatment: The Journey of Radicava and Highlights of Riluzole Formulations

Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...

Find More

ASCO GU 2022 - Urothelial Carcinoma
Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now

Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the results from the DS8201-A-U105 trial (NCT03523572; Active, not recruiting) of Enhertu (trastuzumab deruxtecan) with Opdiv...

Find More

MedTech News and Updates for LivaNova, Medtronic, Conformis, Noninvasix, Masimo
Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study

Noninvasix Granted the US FDA Breakthrough Device Designation for Non-Invasive Monitoring Technology for Sepsis On February 23, 2022, Noninvasix, Inc. received the US FDA breakthrough device designation for its LIVOx™ Central Venous Oxygenation Monitor. It is a non-invasive device and provides real-time, ...

Find More

Leading Medication Management Apps in the Market
How Medication Management Apps are Adding Value to the Treatment Journey?

It has become a necessity in our daily lives to get the medications exactly when the body requires them. But at times, we tend to forget or ignore. Taking medications routinely, understanding their effects and side-effects as well as monitoring the outcomes can be tedious. So healthcare professionals and technologi...

Find More

PARP Inhibitors in Urothelial Carcinoma
PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied in UC in the neoadjuvant, first-line, maintenance therapy, and subsequent lines of the setting. It is worth n...

Find More

pharma-news-for-gsk-idorsia-bms-novartis-lilly-cantex-viatris-biocon
GSK’s Covifenz; Idorsia’s Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business

GSK’s Covifenz, A Plant-Based COVID Vaccine, Receives First Approval The recombinant COVID-19 vaccine developed by Medicago, now known as Covifenz, has received approval in Canada, the company's home country. Covifenz employs Coronavirus-Like Particle (CoVLP) technology, with the vaccine consisting of recombinan...

Find More

Ewing-sarcoma-and-osteosarcoma
Osteosarcoma vs Ewing sarcoma

Osteosarcoma and Ewing sarcoma are two of the most common malignancies of bone tissues present in children. Osteosarcoma treatment usually involves surgery and chemotherapy and Ewing sarcoma treatment typically begins with chemotherapy only. Dr. James Ewing who described the tumor in the 1920’s distinguished the tu...

Find More

Bladder Cancer Highlights ASCO
Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder cancer settings?

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, and Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer are the three ADCs that Seage...

Find More

Renal Cell Carcinoma Highlights- ASCO
ASCO GU 2022: Renal Cell Carcinoma Highlights

Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRC...

Find More